Past Partnerships and Case Studies
The Amphion model has been used to create industry leading and market transforming companies. Several of our successes are highlighted below:
Celgene Corporation is a biopharmaceutical company with a market cap of over $12B engaged in the discovery, development and commercialization of novel therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic and proteomic targets. The Company has three major commercial-stage programs: Thalomid, Focalin (d-MPH) and cellular therapeutics. Thalomid is its lead product and was approved for sale in the United States in 1998. Thalomid is being evaluated in clinical trials for the treatment of solid tumor and hematological cancers, as well as serious inflammatory diseases. The Company also has a preclinical- and clinical-stage pipeline of new drug candidates and cell therapies, highlighted by seven classes of small molecule, orally administered therapeutic agents, including IMiDs (Immunomodulatory Drugs), SelCIDs (Selective Cytokine Inhibitory Drugs), SERMs (Selective Estrogen Receptor Modulators), benzopyrans, kinase inhibitors, tubulin inhibitors and ligase modulators.
Amphion and Celgene working together
Co-founder and lead initial investor in this broad based public biopharmaceutical company. Amphion partners have had active involvement on the board since inception. Provided funding, arranged outside funding and participated in the company's IPO. The Company's market capitalization is now well over $10 billion.
Macromedia, Inc. is a software company with a market cap of well over $1B, whose software enables business users, developers and designers to create and deliver experiences on the Internet, fixed media, wireless and digital devices. The Macromedia MX family of products provides client software, server and development tools for cost-effectively building Websites and Internet applications that offer highly effective end user experiences. Information Convenience Products enable non-technical business users to create and deliver information without intricate technical training. Mobile and Device Products are targeted at device manufacturers, carriers and media networks.
MediSense was an early leader in biosensor technology applied to the home blood glucose monitoring market based on a technology platform licensed from Oxford & Cranfield. MediSense was the first company to commercialize biosensor technology as a pioneer of electrochemical blood glucose testing. In 1994, MediSense Inc. went public in the United States with an initial public offering of 4.5 million shares at $12 per share. Following a number of industry triumphs between 1989 and 1996, Abbott Laboratories acquired the company for $900 million (with sales revenue of $173 million and net income of $31 million), combining the resources and
strengths of the two organizations. Today, Abbott Laboratories, MediSense Products is a leader in the evelopment of innovative products to meet the needs of people living with diabetes.
Amphion and MediSense working together
In 1988, Amphion invested $2 million as seed capital, and subsequently assisted the company in raising an additional $100 million, in which Amphion participated for an additional $10.5 million. After the company's initial public offering in 1994, Amphion continued to assume an aggressive, active posture as an investor, and in 1996 assisted in the sale of MediSense to Abbott Laboratories for $900 million. Amphion was at all times the lead investor and Richard Morgan was Chairman and at one time acting CEO of MediSense.
Quidel Corporation is focused on rapid point of care testing offering a wide breadth of diagnostic products designed to provide accurate, rapid and cost-effective information for acute and chronic conditions for women and their families. A leader in the point-of-care market, Quidel offers diagnostic tests in the areas of respiratory disease, infectious disease, women's health, urinalysis, bone health and autoimmune and complement.
Amphion and Quidel working together
Co-founder and lead initial investor in this broadly based public diagnostics company, focused on rapid point of care testing. We have had active involvement on the board since inception. Provided funding, arranged outside funding and participated in the company's IPO. The Company's market capitalization is about $350 million.
SEQUUS Pharmaceuticals, Inc was acquired by ALZA Corporation (NYSE: AZA) in 1998. The transaction was driven by SEQUUS commercial product portfolio in oncology, which will be used to enhance the merged company's research and development capability. SEQUUS' portfolio of products comprised DOXIL® (doxorubicin HCl liposome injection), an anticancer drug, and AMPHOTEC® (amphotericin B cholesteryl sulfate complex for injection), an antifungal drug. With estimated U.S. sales of $45 million in 1998, DOXIL® was positioned to become one of the largest-selling, ALZA-marketed products.
Amphion and Sequus working together
Co-founder and lead initial investor in this biopharmaceutical company, which developed and marketed liposome-based cancer therapeutics, including Doxil, now a gold standard in chemo therapeutics. We had active involvement on the board from inception through the sale of the company to Alza (now part of J&J) for $750 Million. Provided funding, arranged outside funding and participated in the company's IPO.
VERITAS Software ranks among the top 10 software companies in the world and is the world's leading storage software company, providing data protection, storage management, high availability, disaster recovery, and application performance management software to 99 percent of the Fortune 500.
VERITAS Software offers solutions to the most basic problems of today's data-intensive business environments. Its software products and solutions operate across diverse server, operating system, storage and network environments to provide high availability, protect critical data and guard data against disasters. VERITAS Software solutions ensure that your data is always protected and continually available to keep your business competitive. This range of solutions meets unique reliability, performance, manageability and affordability requirements, enabling VERITAS Software customers to do "more with less" with existing hardware and IT investments.
Vortech Data was a leader in digital image (CT, MRI) management systems. The company was incubated from its earliest conceptual stage by Amphion. In 1993, Vortech partnered with Kodak to convert hospital radiology centers, and was subsequently acquired by Kodak for $130 million. Kodak's Photo CD technology was extended to medical and diagnostic imaging applications as a means to store and distribute high-quality images, regardless of the originating imaging technology. Kodak integrated Kodak Photo CD Medical technology into the Kodak Ektascan Imagelink system to enhance that system's functionality. Developed with Vortech Data, Inc., the Ektascan Imagelink system incorporates a variety of digital components that together provide a comprehensive solution for capturing, networking, storing, and retrieving diagnostic images and patient data.
Amphion and Vortech working together
Amphion started the company when it had no people and no facilities. This was a concept stage company. The first and all subsequent rounds were led by Amphion acting in a lead capacity. Amphion partners were instrumental in hiring and running the company at various stages, managing strategic repositions in response to the market and influencing its successful sale to Kodak.
Click for case study - 51k PDF